·       Industry leader brings deep expertise across neurodegenerative disease therapeutics development

·       Dr Hutton joins Prof. Alessio Ciulli FRS and Dr Adam Gilbert on SAB

Cambridge, UK, 11 November 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the appointment of Dr Mike Hutton to its Scientific Advisory Board (SAB). Mike will provide expert guidance to support the development of the Company’s targeted protein degradation (TPD) TRIMTAC™ and TRIMGLUE™ pipeline, including for Alzheimer’s and Parkinson’s disease targets.

Mike has over 30 years’ experience in neurodegenerative disease research and drug development, including in his previous roles as CSO and Vice President of Neurodegeneration Research and UK Site Scientific Leader at Eli Lilly and Company, where he led on drug discovery for Alzheimer’s Disease, Parkinson’s Disease and fronto-temporal dementia. He has also held a Senior Director role at MSD and was Consultant and Professor of Neuroscience at the Mayo Clinic. Whilst at the Mayo Clinic, Mike’s team was instrumental in identifying the genetic causes of fronto-temporal dementia, including mutations in tau and progranulin. His work on tau led to him receiving the Potamkin and MetLife prizes. Mike holds a BSc in Biochemistry from the University of Manchester and a PhD in Neuroscience from the University of Cambridge.

Dr Nicola Thompson, CEO, TRIMTECH Therapeutics, said: “We’re delighted to welcome Mike as the newest member of our recently formed Scientific Advisory Board¹. His extensive expertise in neurodegenerative disease therapeutics will be a great asset as we continue to advance our mission to deliver first-in-class medicines to address the critical need for cost-effective, disease-modifying treatments for neurodegeneration that can reach broad patient populations.”

Dr Mike Hutton, Scientific Advisor for TRIMTECH Therapeutics, added: “TRIMTECH’s novel approach is leading the way in the development of small molecule CNS penetrant degraders for neurological disorders, addressing the difficult to drug targets underpinning these diseases. I am delighted to join the SAB – the Company has assembled an excellent team, and I look forward to helping guide the development of these much-needed, accessible therapeutic options.”

1. Press Release (2^nd September 2025):https://trimtechtherapeutics.com/trimtech-therapeutics-establishes-scientific-advisory-board/

ENDS

About TRIMTECH Therapeutics Ltd. www.trimtechtherapeutics.com

TRIMTECH Therapeutics is creating novel, highly selective, small molecule targeted protein degraders, to combat neurodegenerative and inflammatory diseases. Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, the Company has demonstrated its ‘TRIMTAC’ degraders can recapitulate degradation seen with other modalities (vectors and antibodies) whilst leaving the functional monomeric form of the target protein intact and able to support healthy cellular function. TRIMTECH’s approach opens up much needed small molecule approaches for indications that affect very large populations, such as Alzheimer’s disease.

TRIMTECH was founded in 2023 by its academic co-founders Leo James, PhD FRS (MRC Laboratory of Molecular Biology) and Will McEwan, PhD (UK Dementia Research Institute, University of Cambridge), with Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther.

TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In March 2025 the Company announced $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.

Find TRIMTECH on LinkedIn and Bluesky